27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
A number of biotech stocks were soaring in Friday's premarket following positive news.
Biogen Idec Inc (NASDAQ: BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037) which showed statistical significance with 3mg, 10mg doses for Alzheimer's treatment.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Biogen Idec traded at $464.71 in the premarket, up 7.16 percent
Gilead Sciences, Inc. (NASDAQ: GILD) moved higher following positive comments from Argus, which expected continued strength for its antiviral and oncology drugs.
Gilead Sciences traded at $102.40, up 0.95 percent.
Prothena Corporation PLC (NASDAQ: PRTA) reported that its PRX002 protein Immunotherapy for Parkinson's Disease met primary objective of Phase 1 study, found to be safe, well tolerated.
Prothena soared to $41.87 in the premarket, up 43.24 percent.
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reported that data showed OCA-treated patients with nonalcoholic steatohepatitis (NASH) saw improvements in its Phase 2b FLINT trial.
Intercept Pharmaceuticals surged 8 percent to $311.71.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.